Platelet Aggregation

• 

  Subject Areas on Research

  • "Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. 
  • A Bigger Look Into the "Therapeutic Window" of Platelet Reactivity to Adenosine Diphosphate. 
  • A meta-analysis and genome-wide association study of platelet count and mean platelet volume in african americans. 
  • A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. 
  • A radioreceptor assay for quantitating plasma factor VIII/von Willebrand's protein. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Abnormalities of platelet aggregation in the vaso-occlusive crisis of sickle-cell anemia. 
  • Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. 
  • Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? 
  • Actions of thrombin in the interstitium. 
  • Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. 
  • Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. 
  • Aggregation of activated platelets with Walker 256 carcinoma cells. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. 
  • Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 
  • Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. 
  • Antiplatelet effects of a novel antianginal agent, nicorandil. 
  • Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 
  • Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. 
  • Antiplatelet resistance--fact or myth? 
  • Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. 
  • Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). 
  • Aspirin and dipyridamole inhibition of collagen-induced platelet aggregation and release in cynomolgus monkeys. 
  • Aspirin resistance and a single gene. 
  • Aspirin resistance. 
  • Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. 
  • Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. 
  • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. 
  • Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. 
  • Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factors. 
  • CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. 
  • Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. 
  • Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues. 
  • Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. 
  • Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. 
  • Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. 
  • Changes in the haemostatic profile during magnesium deficiency in swine. 
  • Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). 
  • Clinical utility of available methods for determining platelet function. 
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). 
  • Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. 
  • Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. 
  • Clopidogrel dosing in overweight patients: does one size fit all? 
  • Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. 
  • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. 
  • Clopidogrel resistance? 
  • Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. 
  • Comparative changes in ventilatory dead space following micro and massive pulmonary emboli. 
  • Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. 
  • Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. 
  • Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. 
  • Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. 
  • Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. 
  • Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor? 
  • Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. 
  • Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. 
  • Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. 
  • Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. 
  • Deficient thromboxane synthesis and response in platelets from premature infants. 
  • Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. 
  • Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. 
  • Differential effects of cytochalasin B on platelet release, aggregation and contractility: evidence against a contractile mechanism for the release of platelet granular contents. 
  • Do NSAIDs interfere with the cardioprotective effects of aspirin? 
  • Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. 
  • Drug insight: Clopidogrel nonresponsiveness. 
  • Drug interactions complicate antiplatelet therapy. 
  • Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Durability of platelet inhibition by clopidogrel. 
  • Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). 
  • Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. 
  • Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. 
  • Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). 
  • Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. 
  • Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. 
  • Effect of magnesium sulphate infusion on ex vivo platelet aggregation in swine. 
  • Effect of nitric oxide synthase inhibition on bleeding time in humans. 
  • Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. 
  • Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. 
  • Effects of 9,12,15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on the platelet aggregation. 
  • Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. 
  • Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. 
  • Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). 
  • Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. 
  • Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. 
  • Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study. 
  • Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. 
  • Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions. 
  • Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. 
  • Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 
  • Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? 
  • Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. 
  • Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. 
  • Evidence for the involvement of platelet glycoproteins other than GP Ib in heparin-associated thrombocytopenia and thrombosis. 
  • Facilitated versus primary PCI for acute myocardial infarction. 
  • Factor VIII/von Willebrand protein. Modification of its carbohydrate causes reduced binding to platelets. 
  • Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. 
  • First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. 
  • First report of the point-of-care TEG: A technical validation study of the TEG-6S system. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets. 
  • Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. 
  • Future alternatives to heparin: low-molecular-weight heparin and hirudin. 
  • Gender differences in platelet GPIIb-IIIa activation. 
  • Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. 
  • Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo. 
  • Hemostatic changes after dietary coenzyme Q10 supplementation in swine. 
  • Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. 
  • Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. 
  • Heparin-induced thrombocytopenia and thrombosis. 
  • Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. 
  • High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? 
  • High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. 
  • Hostility and platelet reactivity in individuals without a history of cardiovascular disease events. 
  • Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. 
  • Identification of alpha-adrenergic receptors in human platelets by [3H]dihydroergocryptine binding. 
  • Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. 
  • Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters. 
  • Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. 
  • Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. 
  • Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. 
  • In vitro effects of acetaminophen and its analogues on human platelet aggregation and thromboxane B2 synthesis. 
  • In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. 
  • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? 
  • Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes. 
  • Infectious and bleeding complications in patients with glycogenosis Ib. 
  • Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. 
  • Inhibited and Uninhibited Platelet Deposition Within a Thrombus: Does It Depend on the Antiplatelet Drug? 
  • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. 
  • Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. 
  • Inhibitors of platelet adhesion. 
  • Inhibitory effect of ristocetin and factor VIII/von Willebrand factor protein on human platelet adenylate cyclase activity. 
  • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. 
  • Insignificant blood damage in calves with a total artificial heart up to six months. 
  • Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. 
  • Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. 
  • Isn't it about time we learned how to use blood transfusion in patients with ischemic heart disease? 
  • Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. 
  • Lack of thromboxane A2 synthesis in platelet aggregation induced by factor VIII/von Willebrand factor. 
  • Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement". 
  • Local administration of L-703,081 using a composite polymeric stent reduces platelet deposition in canine coronary arteries. 
  • Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. 
  • Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. 
  • Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. 
  • Membrane protein mediation of thromboxane A2-induced platelet aggregation. 
  • Menorrhagia in patients with type I glycogen storage disease. 
  • Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. 
  • Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine. 
  • Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. 
  • Modulation of platelet shape and membrane receptor binding by Ca2+-calmodulin complex. 
  • Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something? 
  • Morning blood pressure surge, morning platelet aggregation, and silent cerebral infarction in older Japanese hypertensive patients. 
  • N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. 
  • NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. 
  • Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. 
  • Optimizing platelet P2Y12 inhibition for patients undergoing PCI. 
  • Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. 
  • Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. 
  • Partial expression of GP Ib measured by flow cytometry in two patients with Bernard-Soulier syndrome. 
  • Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events. 
  • Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy. 
  • Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. 
  • Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study. 
  • Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. 
  • Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. 
  • Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study. 
  • Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. 
  • Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. 
  • Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 
  • Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. 
  • Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. 
  • PlA2 polymorphism and efficacy of aspirin. 
  • Platelet Function Testing Before CABG is Recommended in the Guidelines: But Do We Have Enough Evidence? 
  • Platelet activation after stenting with heparin-coated versus noncoated stents. 
  • Platelet activation and its patient-specific consequences. 
  • Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. 
  • Platelet adhesion on a bioresorbable poly(propylene fumarate-co-ethylene glycol) copolymer. 
  • Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Platelet function and pharmacologic inhibition. 
  • Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. 
  • Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window. 
  • Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. 
  • Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. 
  • Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. 
  • Platelet reactivity and thrombogenicity in postmenopausal women. 
  • Platelet reactivity in human aortic grafts: a prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits. 
  • Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. 
  • Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation. 
  • Platelet storage pool deficiency: diagnosis in patients with prolonged bleeding times and normal platelet aggregation. 
  • Platelet tyrosine kinases and fibrinogen receptor activation. 
  • Platelet-mediated thrombolysis in patients with δ-storage pool deficiency: a thrombelastographic analysis. 
  • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. 
  • Point-of-care platelet function analysis ready for prime time? 
  • Polynitrosylated proteins: characterization, bioactivity, and functional consequences. 
  • Prasugrel. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. 
  • Preliminary observations on abnormalities of membrane structure and function in essential hypertension. 
  • Pretreatment with an inhibitor of mac-1 alters regional and systemic platelet function during ischemia-reperfusion in swine. 
  • Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 
  • Priming of platelet alphaIIbbeta3 by oxidants is associated with tyrosine phosphorylation of beta3. 
  • Procoagulant and platelet aggregating properties of antilymphocyte sera. 
  • Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 
  • Prophylaxis of thromboembolism. 
  • Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. 
  • Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. 
  • Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. 
  • Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. 
  • Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. 
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 
  • Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation. 
  • Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. 
  • Refining the treatment of women with unstable angina--a randomized, double-blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable angina. 
  • Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. 
  • Relationship between age and platelet activation in patients with stable and unstable angina. 
  • Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. 
  • Resolution of spontaneous contrast with platelet disaggregatory therapy (trifluoperazine). 
  • Response of platelets exposed to potassium tetraperoxochromate, an extracellular source of singlet oxygen, hydroxyl radicals, superoxide anions and hydrogen-peroxide. 
  • Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. 
  • Response variability and the role of platelet function testing. 
  • Risk of heparin-induced thrombocytopenia from heparin-bonded vascular prostheses. 
  • Role of platelet inhibition in microvascular surgery. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. 
  • S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme. 
  • Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. 
  • Shear-induced aggregation and lysis of platelets. 
  • Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? 
  • Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. 
  • Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein production by human colon carcinoma cells. 
  • Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. 
  • Statins do not affect platelet inhibition with clopidogrel during coronary stenting. 
  • Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains. 
  • Superoxide-independent platelet response to xanthine oxidase. 
  • Surface recruitment but not activation of integrin alpha IIb beta 3 (GPIIb-IIIa) requires a functional actin cytoskeleton. 
  • Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin. 
  • Synthesis of intracellular histamine in platelets is associated with activation of protein kinase C, but not with mobilization of Ca2+. 
  • TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention. 
  • The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. 
  • The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin. 
  • The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. 
  • The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. 
  • The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. 
  • The biochemistry of haemostasis. 
  • The bleeding diathesis in human glycogen storage disease type I: in vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation. 
  • The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity. 
  • The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. 
  • The difference between clopidogrel responsiveness and posttreatment platelet reactivity. 
  • The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. 
  • The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. 
  • The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. 
  • The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effects of magnesium sulfate on maternal and fetal platelet aggregation. 
  • The effects of milrinone on platelets in patients undergoing cardiac surgery. 
  • The empty sack syndrome: a platelet storage pool deficiency associated with empty dense granules. 
  • The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. 
  • The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. 
  • The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. 
  • The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. 
  • The influence of red wine or white wine intake on platelet function and viscoelastic property of blood in volunteers. 
  • The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. 
  • The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. 
  • The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. 
  • The pathogenesis of vascular thrombosis and its impact in microvascular surgery. 
  • The platelet-related effects of tenecteplase versus alteplase versus reteplase. 
  • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. 
  • The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. 
  • The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The role of platelet receptors and adhesion molecules in coronary artery disease. 
  • The role of the porcine von Willebrand factor: baboon platelet interactions in pulmonary xenotransplantation. 
  • The roles of alpha IIb beta 3-mediated outside-in signal transduction, thromboxane A2, and adenosine diphosphate in collagen-induced platelet aggregation. 
  • The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. 
  • Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. 
  • Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. 
  • Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? 
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. 
  • Toward a therapeutic window for antiplatelet therapy in the elderly. 
  • Transient platelet aggregation as a mechanism of unstable angina. Aggressive treatment with coronary angioplasty. 
  • Ultrastructural studies of unstable angina in living man. 
  • Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. 
  • Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade. 
  • Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. 
  • Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. 
  • Vitamin E and total parenteral nutrition. 
  • What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? 
  • Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). 
  • [Aggregation after rehydration of lyophilized platelets]. 
  • eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitro. 
• 

  Keywords of People

  • Erickson, Harold Paul, James B. Duke Distinguished Professor of Cell Biology, Cell Biology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor of Otolaryngology, Surgery, Head and Neck Surgery and Communication Sciences
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology